Full profile
| Also known as | Alpha-tocopherol, Mixed tocopherols |
|---|---|
| Best for | Not featured as a cognitive active — evaluated and graded out on a safety signal · Legitimate use is limited to correcting diagnosed deficiency under clinical supervision |
| Evidence grade | Graded Out — Graded out — evaluated and not featured (failed replication or a safety signal) |
| Studied dose range | Not recommended as a cognitive supplement. For reference: RDA is 15 mg/day; the tolerable upper limit is 1,000 mg/day of any supplemental alpha-tocopherol form, and the harm signals cluster at ≥400 IU/day — at or below the doses studied for brain benefit, so there is no clean therapeutic window for cognition. |
| Time to effect | Not applicable — no reliable cognitive benefit demonstrated in replete adults. |
| Best form | If used for diagnosed deficiency only, natural RRR-alpha-tocopherol (d-alpha) is better absorbed than synthetic all-rac; "mixed tocopherols" marketing does not resolve the safety concern. |
| Food sources | Wheat germ and vegetable oils, Nuts and seeds (almonds, sunflower seeds), Leafy greens, Avocado |
Evidence, honestly graded
Graded out on a safety veto, not an evidence-strength judgment about the nutrient itself. Frank vitamin E deficiency (rare outside malabsorption) does cause neurological harm — but that is repletion, not a nootropic effect. In replete adults the cognitive-prevention evidence is null (PREADViSE, Kryscio 2017), and the supplemental doses historically tested for brain and cardiovascular benefit carry documented safety signals: a dose-response meta-analysis linked ≥400 IU/day to increased all-cause mortality (Miller 2005), and the SELECT trial linked 400 IU/day to increased prostate cancer risk in healthy men (Klein 2011). A transparency-first brand cannot feature, as a cognitive active, a supplement whose studied "benefit" doses raise mortality and cancer risk.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
6,584 licensed natural health products in Health Canada's LNHPD list Vitamin E as a medicinal ingredient.
That makes Vitamin E a recognized, licensable medicinal ingredient in Canada — regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.
Side effects
- Increased bleeding / hemorrhagic-stroke risk at high doses
- Increased all-cause mortality signal at ≥400 IU/day
- Increased prostate cancer risk in healthy men at 400 IU/day
Who should avoid it or check first
- On anticoagulant or antiplatelet therapy
- Before surgery
- Elevated prostate cancer risk
- History of hemorrhagic stroke
Interactions
- Adds to bleeding risk with warfarin and other anticoagulants/antiplatelets
- May interfere with chemotherapy and radiotherapy
- May blunt some statin/niacin lipid effects
Use caution stacking with
- High-dose antioxidant stacks — do not feature vitamin E as a cognitive active
What to look for on a label
- Documented here for transparency — not a featured cognitive active. Any supplemental use should carry the ≥400 IU/day mortality and prostate-cancer safety context and the anticoagulant bleeding caution.
- The tolerable upper limit is 1,000 mg/day supplemental alpha-tocopherol; the doses studied for brain benefit sit in the harm range.
References
- Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (2005). Annals of Internal Medicine, 142(1):37–46High-dose vitamin E (≥400 IU/day) associated with increased all-cause mortality.
- Klein EA, Thompson IM Jr, Tangen CM, et al. (2011). JAMA, 306(14):1549–1556Vitamin E 400 IU/day increased prostate cancer risk.
- Kryscio RJ, Abner EL, Caban-Holt A, et al. (2017). JAMA Neurology, 74(5):567–573No dementia prevention from vitamin E and/or selenium.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-12Graded out
Published straight into Graded Out on a safety veto. In replete adults the cognitive-prevention evidence is null (PREADViSE), and high-dose supplementation carries a documented safety signal — repletion of a true deficiency is not a nootropic effect.
See how Vitamin E compares on grade, dose, and goal in the Evidence Explorer.
